API Imports: Customs Tariff Act 1975 Reconciliation for Formulators

A Tier-1 integrated pharma formulator running a formulation plant at Halol in Gujarat closes November 2025 imports — the second full tax period under the 22 September 2025 GST rate reset. The month’s inbound API pipeline includes forty-seven Bills of Entry: thirty-one filed against ex-Shanghai, ex-Ningbo, ex-Hangzhou and ex-Wuxi (Zhejiang and Jiangsu province) penicillin-family antibiotic suppliers, nine against ex-Qingdao (Shandong province) heterocyclic-nitrogen compound suppliers, and seven against ex-Milan and ex-Genoa (Italy) speciality API suppliers. Each shipment carries a Customs Tariff Act 1975 First Schedule Chapter 29 classification, is assessed at Basic Customs Duty of 7.5 percent, Agriculture Infrastructure and Development Cess of 5 percent, and IGST of 5 percent post the rate reset. The BoE-level reconciliation surface spans the supplier commercial invoice, the Airway Bill or Bill of Lading, the freight forwarder invoice, the ICEGATE Bill of Entry filing, the ICEGATE e-payment duty challan, the warehouse receipt at Halol, the Ind AS 21 foreign exchange translation, and the monthly IGST-import ITC availment against Table 4(A)(1) of the plant’s GSTR-3B. This is API imports Customs Tariff Act 1975 pharma formulator reconciliation at scale, and the discipline that separates a clean monthly close from a compounding rate-timing error is a per-shipment Bill of Entry workbook that ties every document at line-item level and correctly excludes imports from the domestic Section 194Q code 1031 buyer-side TDS mechanism.

Quick reference

The reconciliation in one paragraph

A pharma formulator importing active pharmaceutical ingredients under HSN Chapter 29 of the Customs Tariff Act 1975 First Schedule pays four cash outflows per shipment against one supplier bundle: the supplier commercial invoice in foreign currency (USD or EUR), the freight forwarder invoice for ocean or air freight and insurance, the ICEGATE customs duty challan for BCD plus AIDC plus IGST, and the outbound remittance to the overseas supplier via the authorised dealer bank. Only the IGST leg of the customs duty is creditable — it feeds Table 4(A)(1) of GSTR-3B as IGST-on-import ITC in the tax period of home-consumption clearance and reconciles to the ICEGATE-populated GSTR-2B. BCD and AIDC sit as cost elements in the landed cost per kilogram and flow into the standard cost setting for the Chapter 30 formulation output. The Ind AS 21 foreign exchange translation between the invoice-date rate and the BoE-fortnight CBIC reference rate produces a rate-timing difference that must be documented per BoE. Section 194Q code 1031 does NOT apply — the customs mechanism substitutes — and the AP subledger must carry an import-supplier flag so that no 194Q TDS is mechanically deducted on the outbound remittance. The per-shipment BoE workbook ties every document at line-item level, closes the plant’s monthly IGST-import ITC to GSTR-2B, and feeds the plant P&L a defensible per-kg landed cost.

What the scenario looks like in India

The Indian pharma formulation industry sources between forty and sixty percent of its bulk drug and intermediate requirement from imports, with the dominant supply base concentrated in the Zhejiang, Jiangsu and Shandong provinces of eastern China. Zhejiang hosts a large cluster of penicillin-family and cephalosporin API manufacturers around Hangzhou and Ningbo. Jiangsu hosts heterocyclic-nitrogen and cardiovascular API capacity around Wuxi and Suzhou. Shandong hosts a broad spectrum of intermediate-chemistry API capacity around Qingdao and Jinan. Ex-Italy sourcing — from Milan, Bergamo, Padua and Genoa — anchors the speciality API and complex-chemistry requirement, particularly for oncology, neurology and rare-disease formulations. Ex-US sourcing (Monroe New Jersey and other USFDA-inspected sites) handles the small-volume high-value speciality-API requirement, though the volume share is a fraction of the ex-China leg.

The reference persona for this reconciliation is a Tier-1 integrated formulator operating a formulation plant at Halol in Gujarat — a large-scale finished-dosage-form plant with a mix of tablet, capsule, oral liquid and sterile injectable lines. The plant’s port of import for ex-China and ex-Italy consignments is Nhava Sheva (Jawaharlal Nehru Port, JNPT) on the west coast — a rail plus road inland movement of approximately 400 kilometres brings the customs-cleared warehouse-stock to the Halol plant. Illustrative Tier-1 and Tier-2 formulators with a comparable Halol or Gujarat-cluster formulation footprint that anchors this reconciliation pattern include Sun Pharmaceutical Industries, Zydus Lifesciences, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Cipla, Alembic Pharmaceuticals and Intas Pharmaceuticals. Beyond the Gujarat cluster, the same BoE-level reconciliation discipline applies at Dr Reddy’s Bachupally and Bollaram plants (Telangana, port of import Chennai), Aurobindo Pharma’s Hyderabad-cluster plants, Lupin’s Ankleshwar plant (also Nhava Sheva), Alkem Laboratories’ Ankleshwar and Baddi plants, and Glenmark’s Ankleshwar and Baddi plants.

Volume-wise, a Tier-1 Halol formulation plant handling forty to seventy shipments per month against a monthly landed API purchase of the order of Rs 80 to 150 crore is the operating band that this article addresses. The API vs formulation HSN 2941, 3003, 3004 reconciliation guide walks the standing HSN classification framework that the import cell applies at the BoE filing stage; the reconciliation surface addressed here sits downstream of that classification and covers the four-document tie-out per shipment.

The regulatory overlay — Customs Tariff Act 1975, ICEGATE and IGST on import

Four statutory instruments govern the API import reconciliation cycle.

The Customs Tariff Act 1975, through its First Schedule Chapter 29 for organic chemicals, sets the standing BCD rate on antibiotic APIs at 7.5 percent ad valorem. Chapter 29 heading 2941 covers antibiotics; sub-heading 2941.10 covers penicillins and derivatives with a penicillanic acid structure — Amoxicillin trihydrate, Ampicillin trihydrate, Ampicillin sodium, and related compounds. Sub-heading 2941.20 covers streptomycins, 2941.30 covers tetracyclines, 2941.40 covers chloramphenicol, and 2941.50 covers erythromycin. Non-antibiotic API imports fall under adjacent Chapter 29 headings — 2933 for heterocyclic-nitrogen compounds, 2934 for nucleic-acid derivatives, 2942 for other organic compounds — with their own BCD rates that must be verified against the standing exemption notification for the specific molecule.

The Customs Act 1962 provides the valuation and payment framework. Section 12 charges duty on goods imported into India at the rates specified in the Customs Tariff Act 1975. Section 14 read with the Customs Valuation (Determination of Value of Imported Goods) Rules 2007 provides the assessable-value methodology — the CIF value adjusted for a 1 percent landing charges load. The Bill of Entry is filed electronically at ICEGATE — the Indian Customs Electronic Data Interchange Gateway — and the customs duty is paid via the ICEGATE e-payment challan, generating the actual cash outflow.

The Finance Act 2021, through Section 124, introduced the Agriculture Infrastructure and Development Cess (AIDC) as a levy on specified imported goods effective 2 February 2021. Chapter 29 antibiotic APIs fall within the AIDC schedule at 5 percent on assessable value. AIDC is NOT creditable — it does not feed the electronic credit ledger — and sits as a cost element in the importer’s landed cost workbook.

Section 3(7) of the Customs Tariff Act 1975 read with Section 5(1) of the IGST Act 2017 levies IGST on imported goods at the rate applicable to the corresponding domestic supply. Post the 56th GST Council rate reset effective 22 September 2025, Chapter 29 antibiotic API imports attract IGST at 5 percent on the compound base of assessable value plus BCD plus AIDC. The IGST paid on the BoE is availed as input tax credit under Section 20 IGST Act read with Section 16 CGST Act in the tax period of home-consumption clearance, feeding Table 4(A)(1) of GSTR-3B and auto-reflecting in GSTR-2B via the ICEGATE-GSTN integration.

Section 194Q(5) of the Income-tax Act (as re-enacted under the Income-tax Act 2025 with the SFT payment code 1031 in the CBDT payment schedule) expressly excludes transactions on which a substituting mechanism applies. For imports, the customs mechanism substitutes for the domestic buyer-side TDS on purchase of goods. The AP subledger must carry an import-supplier flag so that the Section 194Q payment code 1031 domestic buyer TDS is NOT mechanically deducted on the outbound remittance to the overseas supplier. Withholding on the outbound remittance to a non-resident is separately governed by Section 195 read with the applicable Double Taxation Avoidance Agreement — for a straight goods import with no royalty or fee-for-technical-services element, Section 195 withholding is typically nil under the business income article of the DTAA.

A worked example — one Amoxicillin trihydrate shipment illustrated end-to-end

Illustrative — the following figures represent the operating pattern of a Tier-1 pharma formulator importing Chapter 29 antibiotic APIs. INR-USD rates and duty rates should be verified against the standing CBIC notifications and the CBIC-notified fortnightly reference rate on the specific BoE date before use.

The Halol formulation plant places a monthly indent for Amoxicillin trihydrate against an ex-Shanghai supplier on a 5,000 kilogram FOB Shanghai basis at USD 8.00 per kilogram. The supplier commercial invoice is dated 3 November 2025 and issued for USD 40,000. The plant’s Ind AS 21 policy rate is the SBI TT selling reference rate on the invoice date, which is INR 83.20 per USD — the AP subledger books the payable at INR 33,28,000. The freight forwarder issues an ocean-freight and marine-insurance invoice covering the Shanghai-to-Nhava Sheva leg at USD 2,000 (ocean freight USD 1,700 plus marine insurance USD 300), taking the notional CIF value to USD 42,000 or approximately USD 8.40 per kilogram.

The customs broker files the Bill of Entry at ICEGATE on 18 November 2025 (the vessel arrives on 15 November, the BoE is filed after the manifest is submitted). The CBIC-notified fortnightly reference rate for BoE assessment for the 16 November to 30 November fortnight is INR 83.00 per USD — the customs assessment uses this rate, producing a CIF INR value of Rs 34,86,000. The Customs Valuation Rules 2007 add the 1 percent landing charges load to arrive at the assessable value of Rs 35,20,860.

The duty computation on the BoE runs as follows. Basic Customs Duty at 7.5 percent on the assessable value of Rs 35,20,860 = Rs 2,64,065. AIDC at 5 percent on the same assessable value of Rs 35,20,860 = Rs 1,76,043. The IGST base is Rs 35,20,860 + Rs 2,64,065 + Rs 1,76,043 = Rs 39,60,968. IGST at 5 percent on Rs 39,60,968 = Rs 1,98,048. Total customs duty payable via the ICEGATE e-payment challan = Rs 2,64,065 (BCD) + Rs 1,76,043 (AIDC) + Rs 1,98,048 (IGST) = Rs 6,38,156.

The landed cost per kilogram at the Halol plant is built as follows: CIF assessable value Rs 35,20,860 + non-creditable BCD Rs 2,64,065 + non-creditable AIDC Rs 1,76,043 = Rs 39,60,968 divided by 5,000 kilograms = Rs 792.19 per kilogram. Adding the customs-clearance handling and inland-freight-from-Nhava-Sheva-to-Halol cost of approximately Rs 8 per kilogram takes the total landed cost at the Halol warehouse to approximately Rs 800 per kilogram — the equivalent of USD 9.60 per kilogram at the invoice-date rate of INR 83.20 per USD, or 20 percent above the FOB Shanghai unit price. The IGST leg of Rs 1,98,048 is availed as input tax credit in the November 2025 tax period, feeding Table 4(A)(1) of the Halol plant’s GSTR-3B and reconciling to the ICEGATE-populated GSTR-2B for the same tax period.

The Ind AS 21 rate-timing difference on the assessable value: the AP subledger books the payable at INR 83.20 (invoice-date rate), while the BoE customs assessment uses INR 83.00 (BoE-fortnight CBIC rate) — a 20-paise-per-USD difference on the USD 40,000 invoice value translates to an INR 8,000 rate-timing gap on the payable. This is documented per BoE in the FX reconciliation ledger and cleared on settlement of the outbound remittance to the ex-Shanghai supplier via the authorised dealer bank (typically 30 to 60 days post BoE clearance depending on the trade credit terms).

Common reconciliation breakages

Five breakages recur across Indian Tier-1 pharma formulators running the API import BoE reconciliation cycle, and each carries a distinct downstream cost.

• Section 194Q code 1031 mis-deducted on outbound remittance to overseas supplier. The most common error is mechanical application of the domestic buyer-side 194Q TDS at 0.1 percent on the AP subledger cumulative purchase register that includes import supplier codes. Section 194Q(5) expressly excludes transactions on which a substituting mechanism applies, and the customs mechanism substitutes for import transactions. The AP subledger must carry an import-supplier flag that suppresses the 194Q code 1031 deduction; failing that, the outbound remittance carries an incorrect withholding, the overseas supplier queries the short-payment, and the buyer must file a refund claim under Section 200A for the excess-deducted TDS while separately reconciling the Form 26AS anomaly.

• Ind AS 21 rate-timing difference between invoice-date and BoE-fortnight rate not captured. The gap between the entity’s invoice-date SBI reference rate (used for AP subledger booking) and the CBIC-notified BoE-fortnight rate (used for customs assessment) is a legitimate rate-timing difference, not a compliance failure. However, formulators that do not capture the difference per BoE lose the audit trail — the year-end aggregate exchange gain or loss line in the P&L does not tie to a bottom-up per-shipment ledger, and any statutory-auditor query cannot be answered without reconstructing every shipment under time pressure.

• AIDC treated as creditable ITC in Table 4 of GSTR-3B. AIDC is NOT input tax credit — it is a cost element in the landed cost. Formulators that mis-classify AIDC as creditable IGST-on-import feed the wrong figure to Table 4(A)(1) of GSTR-3B, over-avail ITC, and face a subsequent GSTR-2B reconciliation mismatch since the ICEGATE reflection surfaces only the IGST leg (Rs 1,98,048 in the worked example above) and not the AIDC leg (Rs 1,76,043). The reversal-with-interest cost under Section 50 CGST Act on the over-availed ITC compounds against the compliance risk.

• Landing charges load applied at the wrong point in the assessable value chain. The 1 percent landing charges load under Customs Valuation Rules 2007 is a load on the CIF value to arrive at the assessable value — not a load on FOB, not a load on assessable value plus BCD, and not a percentage of BCD. Formulators that apply the 1 percent factor at the wrong point in the computation chain distort every downstream duty amount and the IGST-import ITC. The BoE workbook must show the four-line stack — FOB, plus freight-and-insurance to CIF, plus 1 percent landing charges to assessable value, plus BCD plus AIDC to IGST base — as separate columns so the reconciliation to the customs-broker BoE is line-by-line traceable.

• IGST-import ITC availment period misaligned with the BoE home-consumption clearance date. The IGST-import ITC is availed in the tax period in which the BoE is cleared for home consumption — not the tax period of the supplier commercial invoice, not the tax period of the vessel arrival, and not the tax period of the freight forwarder invoice. Formulators that avail the ITC in the wrong tax period distort the GSTR-3B Table 4 filing and, more consequentially, distort the Rule 89(5) inverted-duty refund workbook for the plant’s Chapter 30 formulation output for the same period since the 5 percent IGST-import ITC on API is a significant component of the Net ITC composition.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the ICEGATE Bill of Entry data, the supplier commercial invoice from the AP subledger, the freight forwarder invoice, the customs duty payment challan and the plant’s GSTR-2B ICEGATE-reflected IGST-import ITC — and produces a per-shipment BoE-level landed cost workbook that ties every document at line-item level, computes the Ind AS 21 rate-timing difference between the invoice-date and the BoE-fortnight CBIC reference rate, feeds the correct IGST-import ITC to Table 4(A)(1) of GSTR-3B, holds BCD and AIDC as non-creditable cost elements in the plant’s per-kilogram landed cost, and flags every import supplier code as Section 194Q code 1031 non-applicable so the domestic buyer-side TDS mechanism does not mis-fire on outbound remittances. Match rate improvement of 51 to 88 percent on the BoE-to-GSTR-2B reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-1 pharma formulator running a multi-plant import-heavy Chapter 30 network rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The BoE-level API import reconciliation documented here sits alongside the backward integration API manufacturing transfer pricing walkthrough for the alternative sourcing model — where the formulator sources its APIs from an in-group captive API plant under Section 92BA Specified Domestic Transaction rules rather than from an overseas supplier. The two paths — external import versus captive backward integration — carry different tax, transfer-pricing and inversion-cycle consequences that the finance team must model side by side when sizing the medium-term API-sourcing strategy.

The IGST-import ITC on Chapter 29 API feeds the plant’s Rule 89(5) inverted-duty refund workbook — read the Wave A Rule 89(5) inverted-duty refund pharma formulations complete guide for the downstream refund mechanic against the plant’s 5 percent Chapter 30 output. The equivalent import-mechanic reconciliation for a different sector, where BCD applies to cotton and man-made fibre imports under HSN Chapter 52 and 54, sits at BCD, cotton and MMF textile import reconciliation — the same Customs Tariff Act 1975 First Schedule framework applied to a different tariff chapter.

The Section 194Q code 1031 domestic buyer-side TDS reference — critical for the AP-subledger import-supplier flag design — sits at TDS payment code 1031 for Section 194Q purchase of goods. The methodology framework for building the per-shipment BoE reconciliation workbook — mapping every document to a distinct reconciliation surface, capturing the rate-timing difference per BoE, and closing the monthly IGST-import ITC to GSTR-2B — sits in Terra Insight’s reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the IGST-import ITC-to-GSTR-2B reconciliation workflow.

The five FAQs below address the operational questions Indian pharma import cells and formulation-plant controllers ask most often when building a standing monthly BoE-level API import reconciliation cycle under the Customs Tariff Act 1975 First Schedule Chapter 29.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 15 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024